Hong Kong Pharma Enters Underwriting Agreement
Ticker: HKPD · Form: 6-K · Filed: Jan 17, 2025 · CIK: 2007702
Sentiment: neutral
Topics: underwriting-agreement, material-definitive-agreement, capital-raising
TL;DR
HK Pharma inks underwriting deal with Bancroft Capital, paving way for potential offering.
AI Summary
On January 14, 2025, Hong Kong Pharma Digital Technology Holdings Limited entered into an Underwriting Agreement with Bancroft Capital, LLC. This agreement outlines the terms for the sale of securities, with Bancroft Capital acting as the representative for the underwriters. The filing is a Report of Foreign Private Issuer for the month of January 2025.
Why It Matters
This agreement signifies a step towards potential capital raising or public offering activities for the company, which could impact its financial structure and market presence.
Risk Assessment
Risk Level: medium — Entering into an underwriting agreement can indicate a need for capital or a planned offering, which carries inherent market and execution risks.
Key Players & Entities
- Hong Kong Pharma Digital Technology Holdings Limited (company) — Registrant
- Bancroft Capital, LLC (company) — Underwriter Representative
- January 14, 2025 (date) — Date of Underwriting Agreement
FAQ
What is the purpose of the Underwriting Agreement?
The filing states that the Underwriting Agreement is a Material Definitive Agreement, indicating it outlines terms for the sale of securities, with Bancroft Capital, LLC acting as the representative of the underwriters.
Who is the underwriter involved in this agreement?
Bancroft Capital, LLC is named as the representative of the underwriters in the Underwriting Agreement.
When was the Underwriting Agreement entered into?
The Underwriting Agreement was entered into on January 14, 2025.
What type of filing is this for Hong Kong Pharma Digital Technology Holdings Limited?
This is a Form 6-K, a Report of Foreign Private Issuer, for the month of January 2025.
Does the company file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under cover of Form 20-F.
Filing Stats: 1,190 words · 5 min read · ~4 pages · Grade level 16.1 · Accepted 2025-01-17 16:00:25
Key Financial Figures
- $0.001 — s (the “Shares”), par value $0.001 per share (the “Ordinary Shares&r
- $4.00 — ”), at a public offering price of $4.00 per share (the “Offering Price&rd
- $3.72 — e Representative at a purchase price of $3.72 (93% of the Offering Price). The Compan
- $5,614,740, b — e gross proceeds from the Offering were $5,614,740, before deducting underwriting discounts a
- $4,000,000 — s and other related expenses, including $4,000,000 received by the Company and $1,614,740
- $1,614,740 — $4,000,000 received by the Company and $1,614,740 received by the Selling Shareholders.
- $4.80 — o July 15, 2028 at an exercise price of $4.80 per share (120% of the Offering Price).
Filing Documents
- ea0227928-6k_hong.htm (6-K) — 25KB
- ea022792801ex1-1_hong.htm (EX-1.1) — 319KB
- ea022792801ex3-1_hong.htm (EX-3.1) — 261KB
- ea022792801ex4-1_hong.htm (EX-4.1) — 90KB
- ea022792801ex99-1_hong.htm (EX-99.1) — 11KB
- ea022792801ex99-2_hong.htm (EX-99.2) — 10KB
- 0001213900-25-004593.txt ( ) — 717KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 17, 2025 HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITED By: /s/ Lap Sun Wong Lap Sun Wong Chief Executive Officer and Chairman 4